J. Sato et al., URINARY-EXCRETION OF MEFENAMIC-ACID AND ITS METABOLITES INCLUDING THEIR ESTERGLUCURONIDES IN PRETERM INFANTS UNDERGOING MEFENAMIC-ACID THERAPY, Biological & pharmaceutical bulletin, 20(4), 1997, pp. 443-445
Urinary excretion of mefenamic acid (MA) and its two oxidative metabol
ites, M-I (3'-hydroxymethyl derivative) and M-II (3'-carboxyl derivati
ve), and their glucuronides was investigated in preterm infants underg
oing MA therapy. MA was given orally at a dose of 2 mg/kg and the dose
was repeated every 24 h a maximum of three times. Urine was collected
for up to 5 d after the last dose, and MA and the metabolites mere de
termined by a newly developed HPLC. The cumulative amounts of MA and t
he metabolites excreted in the urine varied from 7 to 46% of the total
dose administered, and mere less than those reported in adults and ch
ildren. Significant correlation was observed between the plasma half-l
ife of MA and the cumulative amount of MA and the metabolites excreted
in the urine. These results suggest that long plasma half-lives of MA
observed in preterm infants are due mainly to low activity of drug me
tabolizing enzyme(s). In an infant who received the two regimens of MA
therapy about 2 weeks apart, the plasma half-life of MA was shortened
and the urinary excretion of the MA metabolites including their glucu
ronides was greatly increased during this period. It is suggested that
the activities of both cytochrome P-450(s) and glucuronyltransferase(
s) related to MA metabolism rapidly increased during the first month o
f the infant's life.